The United States Food and Drug Administration (FDA) has issued a formal warning letter to Exactech, a prominent manufacturer of orthopedic implants, following a detailed inspection of its production facility in Sarasota, Florida. The regulatory action highlights significant systemic failures in quality control, manufacturing specifications, and environmental monitoring, marking another chapter in the company’s ongoing struggle with regulatory compliance and product reliability. The inspection, conducted in July 2024, revealed that the facility lacked the necessary rigor required to ensure the safety and effectiveness of its orthopedic products, particularly its polyethylene-molded components and shoulder replacement systems.
At the time of the FDA’s site visit, Exactech was navigating a period of intense corporate transition. The company had not yet received court approval for the sale of its assets, a process that eventually led to the launch of Advita Ortho. However, the regulatory findings suggest that the internal quality management systems remained deficient during this critical window. The warning letter specifically identifies a failure to establish and maintain adequate procedures for finished device acceptance and production controls, raising concerns about the integrity of medical devices already in the market or slated for distribution.
Detailed Deficiencies in Manufacturing Specifications and Supplier Oversight
One of the most critical findings in the FDA warning letter pertains to the lack of stringent specifications for raw materials. Inspectors discovered that Exactech had failed to define essential testing protocols and specifications for the polymer powder used in the fabrication of polyethylene-molded products. Polyethylene is a fundamental material in orthopedic surgery, often serving as the bearing surface in knee and hip replacements. Its quality is paramount; any variation in the density or purity of the powder can lead to premature wear, oxidation, and the eventual failure of the implant, necessitating painful and complex revision surgeries for patients.
The FDA noted that Exactech did not conduct necessary audits of its third-party powder suppliers. In the highly regulated medical device industry, manufacturers are required to verify that their suppliers meet strict quality standards through regular inspections and data verification. By failing to audit these outside entities, Exactech lacked the objective evidence needed to confirm that the raw materials met the technical requirements for human implantation. This lapse in oversight creates a blind spot in the supply chain, potentially allowing substandard materials to enter the manufacturing pipeline.
Furthermore, the Sarasota facility was found to be operating without comprehensive work instructions for specific high-stakes products. The FDA highlighted the Equinoxe Torque Screw and the Equinoxe Shoulder Liner devices as areas of particular concern. Work instructions are the "blueprints" of the manufacturing floor, ensuring that every operator performs tasks with consistency. Without these instructions, the risk of human error increases exponentially. The warning letter documented a specific instance where a facility operator passed a screw through the inspection process despite the fact that its measurements deviated from the required standards. This error was only caught upon a retrospective review of the measurements by FDA inspectors, suggesting that the facility’s internal "checks and balances" were non-functional.
Environmental Control Failures and Material Integrity
The FDA’s investigation extended beyond the assembly line to the very atmosphere of the manufacturing plant. Regulatory standards require medical device facilities to maintain strictly controlled environments, as fluctuations in temperature and humidity can alter the physical properties of surgical materials. From March 2024 through the date of the warning letter, monitoring data from the Sarasota site showed consistent excursions where allowable temperature and humidity levels were exceeded.
According to the inspectors, Exactech attempted to address these frequent excursions not by fixing the climate control systems, but by changing the specifications to allow for higher variances. The FDA criticized this approach, noting that historical data showed the facility was unable to stay within the original, safer parameters. High moisture levels are particularly dangerous for medical-grade polymers and metals, as humidity can affect the strength of materials and the efficacy of sterilization processes. For a company already reeling from past issues involving material degradation, these environmental lapses represent a significant regulatory red flag.
A Chronology of Quality Issues and Legal Challenges
The recent warning letter is not an isolated incident but rather the latest in a series of setbacks for the Florida-based manufacturer. To understand the gravity of the current FDA action, it is necessary to examine the timeline of Exactech’s regulatory and legal history:
- 2021–2022: Large-Scale Recalls. Exactech initiated significant recalls affecting hundreds of thousands of knee, hip, and ankle implants. The primary issue involved defective vacuum-seal packaging that allowed oxygen to reach the polyethylene inserts. This led to premature oxidation, which made the plastic brittle and prone to cracking inside patients’ bodies.
- September 2024: False Claims Act Settlement. Just months before the disclosure of the current warning letter, Exactech agreed to pay $8 million to the U.S. government. The settlement addressed allegations that the company knowingly sold defective knee implants to federal healthcare programs, including Medicare and the VA, between 2004 and 2022. The government alleged that the company was aware of the packaging defects long before taking comprehensive corrective action.
- October 2024: Bankruptcy and Asset Sale. Facing thousands of liability lawsuits from patients who received defective implants, Exactech filed for Chapter 11 bankruptcy protection. As part of this process, the company entered into an agreement to sell its assets to a group of investors, leading to the formation of Advita Ortho.
- July 2024 (Inspection Date): The FDA conducts the inspection in Sarasota that forms the basis of the current warning letter.
This timeline illustrates a pattern of systemic failures that have persisted despite multiple interventions by federal authorities and the mounting cost of legal settlements.
Documentation Gaps and Nonconformance Management
A recurring theme in the FDA’s warning is the lack of "traceability" and "accountability" in the manufacturing process. Between July 2023 and July 2025 (as cited in the regulatory findings regarding the tracking period), Exactech maintained incomplete documentation for production events. Specifically, the company failed to adequately document instances where products deviated from process specifications.
In a compliant manufacturing environment, any deviation must be logged as a "nonconformance." This trigger-points an investigation to determine why the deviation happened and whether the affected batch of products is safe for use. By failing to maintain these records, Exactech made it nearly impossible to track which specific units were affected by process errors. This lack of data integrity undermines the entire Quality Management System (QMS), as it prevents the company from performing effective root-cause analysis or implementing corrective and preventive actions (CAPA).
Official Responses and Corporate Transition
While Exactech has not issued a lengthy public rebuttal to the warning letter, the company has historically stated its commitment to patient safety and quality. During the bankruptcy proceedings, leadership emphasized that the transition to Advita Ortho was intended to provide a "fresh start" with a renewed focus on innovation and clinical excellence.
However, the FDA’s findings put the new entity, Advita Ortho, in a difficult position. While the asset sale may have cleared some financial hurdles, the operational deficiencies identified at the Sarasota facility are "inherited" problems. Regulatory experts suggest that the FDA will likely require a total overhaul of the Sarasota site’s quality systems before the agency considers the matter resolved. Failure to address the warning letter’s requirements could lead to more severe actions, including a court-ordered injunction, the seizure of products, or the assessment of civil money penalties.
Broader Implications for the Orthopedic Industry
The situation at Exactech serves as a cautionary tale for the broader medical device industry. It highlights the FDA’s increasing focus on "Quality by Design" and the necessity of maintaining environmental controls. For surgeons and healthcare providers, the recurring issues at Exactech have created a crisis of confidence. Many hospitals have had to implement specialized monitoring programs for patients who received Exactech implants to detect early signs of device failure.
From a market perspective, the instability of a major player like Exactech allows competitors in the orthopedic space—such as Zimmer Biomet, Stryker, and DePuy Synthes—to capture market share. However, the regulatory scrutiny applied to Exactech often signals a broader trend where the FDA may increase inspections across the sector to ensure that other manufacturers are not cutting similar corners in supplier oversight or climate control.
Analysis of the Path Forward
For the Sarasota facility to regain compliance, several high-priority steps must be taken. First, the company must perform a comprehensive validation of all manufacturing equipment and environmental systems. This includes upgrading HVAC systems to ensure that temperature and humidity remain within tight tolerances, regardless of external Florida weather conditions.
Second, the company must implement a robust supplier qualification program. This involves not just reviewing paperwork from suppliers, but performing on-site audits and independent laboratory testing of raw materials like polyethylene powder.
Finally, the "human element" of quality control requires immediate attention. The instance of an inspector passing a defective screw suggests a need for better training, clearer digital work instructions, and perhaps the implementation of automated optical inspection (AOI) systems that remove the potential for human bias or error in measuring critical dimensions.
The FDA has given the company a standard window to respond with a detailed plan of corrective actions. The medical community and the thousands of patients currently living with Exactech-manufactured devices will be watching closely to see if the transition to Advita Ortho brings about the systemic changes necessary to ensure that "quality" is more than just a corporate buzzword. The road to recovery for the Sarasota facility will be long, and the shadow of the $8 million settlement and the ongoing bankruptcy proceedings continues to loom over the company’s efforts to rebuild its reputation.